Spot on, the primary value would be to bundle up with a statin, offer as a single treatment. And yes, should have no probs with patenting that its a new treatment.
Secondary value as a stand alone treatment for those where a statin is ineffective. Could licence out right to use in conjunction with statin, and retain stand alone use development... a few options I suppose.
bull case, page-117
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.2¢ |
Change
-0.001(1.59%) |
Mkt cap ! $11.12M | |||
| Open | High | Low | Value | Volume |
| 6.3¢ | 6.5¢ | 6.2¢ | $3.61K | 56.74K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 6.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.2¢ | 80 | 1 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.3¢ |
Change
-0.001 ( 1.56 %) |
||||
| Open | High | Low | Volume | ||
| 6.3¢ | 6.3¢ | 6.3¢ | 43043 | ||
| Last updated 15.09pm 24/05/2024 ? | |||||
| NYR (ASX) Chart |